SPIRIVA®* celebrates 10 years of ongoing commitment to patients and advancing clinical innovation in COPD
3 September 2012 | By Boehringer Ingelheim
SPIRIVA® is the most prescribed COPD maintenance treatment worldwide...
List view / Grid view
3 September 2012 | By Boehringer Ingelheim
SPIRIVA® is the most prescribed COPD maintenance treatment worldwide...
3 September 2012 | By Boehringer Ingelheim
“These results exceeded our expectations..."
30 August 2012 | By Boehringer Ingelheim
European approval for the MycoFLEX® Headspace bottle...
29 August 2012 | By Boehringer Ingelheim
New one-year follow-up results from the global RE-LY AF registry...
27 August 2012 | By Boehringer Ingelheim
40,000 people estimated to be saved from a stroke related to non-valvular atrial fibrillation...
27 August 2012 | By Boehringer Ingelheim
New data to be presented at the Annual Congress of the ERS 2012...
24 August 2012 | By Boehringer Ingelheim
Indirect comparison based on the RE-LY® trial and the Rocket AF trial suggests advantages of Pradaxa® in stroke prevention in patients with atrial fibrillation...
17 August 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta® (linagliptin) tablets for use as add-on therapy to insulin.
14 August 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has grown again in the current financial year...
3 August 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announced an agreement with Servier & its partner XOMA Corporation...
25 July 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) received Marketing Authorisation from the European Commission for Jentadueto® which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. 1 Linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes. 1
23 July 2012 | By Boehringer Ingelheim
FX125L is a small molecule...
16 July 2012 | By Boehringer Ingelheim
This year's Boehringer Ingelheim FENS Award was granted to Ilka Diester...
10 July 2012 | By Boehringer Ingelheim
Boehringer Ingelheim is concentrating on new business models...
9 July 2012 | By Boehringer Ingelheim
"We are very pleased to sponsor the joint research programs..."